NEW YORK (GenomeWeb News) – PerkinElmer has acquired two separate companies, one in China and one in India, in a bid to expand its diagnostics and genetic screening businesses.
The firm said that it has completed its acquisition of SYM-BIO Lifescience, a Shanghai, China-based diagnostics firm for around $63.7 million in cash. SYM-BIO supplied Chinese hospitals with infectious disease diagnostic products. PerkinElmer said that the acquisition doubles its access to hospitals in China, offering the firm a larger base to expand its prenatal and newborn screening business.
The deal also provides PerkinElmer with "substantial" manufacturing plant capacity in Shanghai and the surrounding area.
PerkinElmer also announced that it has acquired the genetic screening business of Surendra Genetic Labs, a lab in Chennai, India, that provides fetal, maternal, and newborn screening.
The firm did not disclose the financial terms of that pact.